BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 12602508)

  • 1. Nitric oxide and portal hypertension.
    González-Abraldes J; García-Pagán JC; Bosch J
    Metab Brain Dis; 2002 Dec; 17(4):311-24. PubMed ID: 12602508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current concepts on the role of nitric oxide in portal hypertension.
    Hu LS; George J; Wang JH
    World J Gastroenterol; 2013 Mar; 19(11):1707-17. PubMed ID: 23555159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis.
    Bolognesi M; Di Pascoli M; Verardo A; Gatta A
    World J Gastroenterol; 2014 Mar; 20(10):2555-63. PubMed ID: 24627591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology and a Rational Basis of Therapy.
    Gracia-Sancho J; Maeso-Díaz R; Bosch J
    Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension].
    Kim MY; Baik SK
    Korean J Gastroenterol; 2009 Sep; 54(3):143-8. PubMed ID: 19844149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.
    Fiorucci S; Antonelli E; Tocchetti P; Morelli A
    Cardiovasc Drug Rev; 2004; 22(2):135-46. PubMed ID: 15179450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of portal hypertension.
    Iwakiri Y
    Clin Liver Dis; 2014 May; 18(2):281-91. PubMed ID: 24679494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis.
    Møller S; Bendtsen F
    Liver Int; 2018 Apr; 38(4):570-580. PubMed ID: 28921803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology of portal hypertension.
    Bosch J; Pizcueta P; Feu F; Fernández M; García-Pagán JC
    Gastroenterol Clin North Am; 1992 Mar; 21(1):1-14. PubMed ID: 1568769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodynamic changes in portal hypertension: new insights in the pathogenesis and clinical implications.
    Michielsen PP; Pelckmans PA
    Acta Gastroenterol Belg; 1994; 57(2):194-205. PubMed ID: 8053307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance.
    Wiest R; Groszmann RJ
    Semin Liver Dis; 1999; 19(4):411-26. PubMed ID: 10643626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis.
    Di Pascoli M; Sacerdoti D; Pontisso P; Angeli P; Bolognesi M
    J Vasc Res; 2017; 54(2):92-99. PubMed ID: 28402977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis.
    Grace JA; Klein S; Herath CB; Granzow M; Schierwagen R; Masing N; Walther T; Sauerbruch T; Burrell LM; Angus PW; Trebicka J
    Gastroenterology; 2013 Oct; 145(4):874-884.e5. PubMed ID: 23796456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic, splanchnic and systemic haemodynamic abnormalities in portal hypertension.
    Bosch J; Pizcueta MP; Fernández M; Feu F; Cirera I; Luca A; García-Pagán JC
    Baillieres Clin Gastroenterol; 1992 Sep; 6(3):425-36. PubMed ID: 1421593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of portal hypertension.
    Cichoz-Lach H; Celiński K; Słomka M; Kasztelan-Szczerbińska B
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():231-8. PubMed ID: 18812641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of extrahepatic vasodilation in portal hypertension.
    Hennenberg M; Trebicka J; Sauerbruch T; Heller J
    Gut; 2008 Sep; 57(9):1300-14. PubMed ID: 18445644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension.
    Iwakiri Y
    J Clin Gastroenterol; 2007; 41 Suppl 3():S288-94. PubMed ID: 17975478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nitric oxide in portal hypertensive systemic and portal vascular pathology.
    Hartleb M; Michielsen PP; Dziurkowska-Marek A
    Acta Gastroenterol Belg; 1997; 60(3):222-32. PubMed ID: 9396180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats.
    Van de Casteele M; Hösli M; Sägesser H; Reichen J
    J Hepatol; 1999 Aug; 31(2):300-5. PubMed ID: 10453944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.